Ask Warren

Dongwha Pharm

000020 · KOSPI · ₩000020 · 동화약품

₩5,100▼ ₩60 (1.16%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −18.14%
Market cap
₩142B
Enterprise value
₩228B
P/E
7.9×
P/B
0.4×
Dividend yield
1.3%
ROE
4.6%
Net margin
3.5%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−32.5% from the high

₩4,450Today: ₩5,020 – ₩5,210₩7,560

Returns

  • 1W−3.0%
  • 1M+0.8%
  • 3M+9.0%
  • 6M−15.8%
  • YTD−18.4%
  • 1Y−18.1%
Volume today
102,166
0.2× the 20-day average
Traded today
₩520M
Listed shares
27,931,470
EPS (12 months)
₩647
Earnings yield 12.7%
SellBuy
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

26Quiet
  • BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
  • MomentumFlat0.6% over the last month; the price is below its 20-day average.
  • News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.

Signals describe activity, not recommendations. Not financial advice.

Dongwha Pharm stock overview

Dongwha Pharm (동화약품, KRX: 000020) is listed on KOSPI, in the Biotech & Pharma sector. Donghwa Pharmaceutical Co. Its shares closed at ₩5,100 on Oct 30, 2026, down 1.16% on the day, giving it a market value of ₩142B.

Key facts

Market cap
₩142B
Sector
Biotech & Pharma
Latest price change
−1.16%
As of
Oct 30, 2026
Main business
Donghwa Pharmaceutical Co.

Quick answers about Dongwha Pharm

What does Dongwha Pharm do?
Donghwa Pharmaceutical Co. is a Korean company operating in pharmaceuticals, medical devices, and other financial investments, with pharmaceutical products making up the largest share of its business. Its pharmaceutical lineup includes over-the-counter and prescription drugs such as Gas Hwal-myungsu, Fucidin, Pancol, and Lacor, while its medical device subsidiary Medicey manufactures orthopedic implants.
What is the market cap of Dongwha Pharm?
The market capitalisation of Dongwha Pharm was ₩142B at the close on Oct 30, 2026.
Who are the largest shareholders of Dongwha Pharm?
According to the latest official filings, the largest reported holders are Yoon Do-jun (33.82%, as of Aug 11, 2026); Yun In-ho (6.43%, as of Mar 24, 2025); Yoon Gil-jun (1.84%, as of Apr 16, 2025).
When is the next earnings report from Dongwha Pharm?
Korean companies rarely announce results dates in advance. Based on when Dongwha Pharm filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
Does the National Pension Service own Dongwha Pharm?
Yes. The National Pension Service held 0.61% of Dongwha Pharm shares as of Dec 31, 2025.

Company profile

Donghwa Pharmaceutical Co. is a Korean company operating in pharmaceuticals, medical devices, and other financial investments, with pharmaceutical products making up the largest share of its business. Its pharmaceutical lineup includes over-the-counter and prescription drugs such as Gas Hwal-myungsu, Fucidin, Pancol, and Lacor, while its medical device subsidiary Medicey manufactures orthopedic implants. The group also runs a drugstore chain through TS Care in Vietnam and reports sales in both Korea and overseas markets.

Written by AI from the company's latest annual report.

Korean name
동화약품
Sector
Biotech & Pharma
Themes
Pharmaceuticals
CEO
유준하, 윤인호(각자 대표이사)
Founded
Sep 1897
Listed
Mar 1976
Listed shares
27,931,470
Fiscal year ends
Month 12
Website
www.dong-wha.co.kr

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: Dongwha Pharm / 동화약품 / 000020 / KRX:000020

Source: KRX statistical information